Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Dupont

Showing results (61-70 of 552) with videos related to

Pageof 56
Sort By:
Cellular Immunology|October 1, 1984
Deficient natural killer function in patients receiving immunosuppressive drugs: analysis at the cellular levelE Dupont, M Vandercruys, J Wybran
Vox Sanguinis|January 1, 1997
Increased in vitro immunosuppressive action of anti-CMV and anti-HBs intravenous immunoglobulins due to higher amounts of interferon-gamma specific neutralizing antibodiesC Denys, M Toungouz, E Dupont
Acta Neurologica Scandinavica|September 1, 1985
Progabide in the treatment of hyperkinetic extrapyramidal movement disordersK Mondrup, E Dupont, H Braendgaard
International Journal of Cosmetic Science|February 15, 2013
Beyond UV radiation: a skin under challengeE Dupont, J Gomez, D Bilodeau
Journal of Neurology, Neurosurgery, and Psychiatry|April 1, 1986
Mesulergine in early Parkinson's disease: a double blind controlled trialE Dupont, B Mikkelsen, J Jakobsen
Current Opinion in Clinical Nutrition and Metabolic Care|August 24, 1999
Clinical use of lipid emulsionsI E Dupont, Y A Carpentier
Acta Neurologica Scandinavica|July 1, 1977
Theophyllamine and the antiparkinsonian response to levodopa treatmentI Magnussen, E Dupont, P Jakobsen
American Journal of Physiology. Cell Physiology|August 26, 2011
No muscle atrophy without GSK-3β. Focus on "Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy"Esther E Dupont-Versteegden, Christine Waters
Acta Neurologica Scandinavica|October 1, 1983
The effect of the GABA-agonist, progabide, on benign essential tremor. A controlled clinical trialK Mondrup, E Dupont, E Pedersen
Lancet (London, England)|December 24, 1983
GABA receptor agonists in intention myoclonusK Mondrup, E Dupont, H Braendgaard
Pageof 56

Showing results (61-70 of 552) with videos related to

Sort By:
Pageof 56
Cellular Immunology|October 1, 1984
Deficient natural killer function in patients receiving immunosuppressive drugs: analysis at the cellular levelE Dupont, M Vandercruys, J Wybran
Vox Sanguinis|January 1, 1997
Increased in vitro immunosuppressive action of anti-CMV and anti-HBs intravenous immunoglobulins due to higher amounts of interferon-gamma specific neutralizing antibodiesC Denys, M Toungouz, E Dupont
Acta Neurologica Scandinavica|September 1, 1985
Progabide in the treatment of hyperkinetic extrapyramidal movement disordersK Mondrup, E Dupont, H Braendgaard
International Journal of Cosmetic Science|February 15, 2013
Beyond UV radiation: a skin under challengeE Dupont, J Gomez, D Bilodeau
Journal of Neurology, Neurosurgery, and Psychiatry|April 1, 1986
Mesulergine in early Parkinson's disease: a double blind controlled trialE Dupont, B Mikkelsen, J Jakobsen
Current Opinion in Clinical Nutrition and Metabolic Care|August 24, 1999
Clinical use of lipid emulsionsI E Dupont, Y A Carpentier
Acta Neurologica Scandinavica|July 1, 1977
Theophyllamine and the antiparkinsonian response to levodopa treatmentI Magnussen, E Dupont, P Jakobsen
American Journal of Physiology. Cell Physiology|August 26, 2011
No muscle atrophy without GSK-3β. Focus on "Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy"Esther E Dupont-Versteegden, Christine Waters
Acta Neurologica Scandinavica|October 1, 1983
The effect of the GABA-agonist, progabide, on benign essential tremor. A controlled clinical trialK Mondrup, E Dupont, E Pedersen
Lancet (London, England)|December 24, 1983
GABA receptor agonists in intention myoclonusK Mondrup, E Dupont, H Braendgaard
Pageof 56